Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | GCK | P35557 | 3/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186557 | 0.83 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL610994 | 0.79 | IGF1R (0.36) | SMN1; SMN2BTKIGF1R | |
| SCHEMBL24375281 | 0.78 | BTK (0.38) | BTKAURKAAURKB | |
| SCHEMBL608710 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1LMNABTKAURKA | |
| SCHEMBL161634 | 0.77 | MEN1 (0.47) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL173303 | 0.77 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL162573 | 0.76 | MKNK2 (0.52) | — | |
| SCHEMBL14918821 | 0.75 | MAPT (0.39) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL1393128 | 0.75 | SYK (0.41) | TYK2BTKSYK | |
| SCHEMBL14912741 | 0.75 | PIK3C3 (0.40) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403846-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-11-02 | — | — | EP | disclosed |
| EP-2297142-B1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | HOFFMANN LA ROCHE (CH) | 2015-10-14 | — | — | EP | disclosed |
| US-8822457-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822457-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8618098-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2242749-B1 | NOVEL PYRIDINONES AND PYRIDAZINONES | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2009156284-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009098144-A1 | NOVEL PYRIDINONES AND PYRIDAZINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | BTK, LCK, SYK | NPC1 4499/4885RAB9A 1900/4885SMN1; SMN2 3904/4885 |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | NPC1 4613/4885RAB9A 2578/4885SMN1; SMN2 3803/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | NPC1 4638/4885RAB9A 2693/4885SMN1; SMN2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.